News
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Zacks Investment Research on MSN1h
Septerna Stock Surges on Oral Obesity Drug Deal With Novo NordiskShares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
MarketBeat on MSN2h
Is It Time to Buy the Dip in Novo Nordisk Stock?CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
Dow Jones Top Company Headlines at 9 PM ET: UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud | Dickâs ... UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud ...
Dow Jones Top Company Headlines at 7 PM ET: Cisco Systems Boosts Outlook After Posting Higher Profit, Sales | Dickâs ... Cisco Systems Boosts Outlook After Posting Higher Profit, Sales The ...
Diversified healthcare company CVS Health (NYSE:CVS) announced better-than-expected revenue in Q1 CY2025, with sales up 7% ...
Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback